Lung cancer biomarker
KRAS G12C in lung cancer: what does the result mean for targeted therapy questions?
KRAS G12C is a molecular alteration that can shape treatment discussions. Decisions still depend on stage, prior therapy, current status, and local access.
This may be relevant if
- An NGS or molecular report mentions KRAS G12C.
- You want to understand targeted therapy or treatment sequence questions.
- The case has progressed and needs new questions for the treating team.
What information matters?
Start with what you have. Missing information can be marked and completed later.
- Variant name and testing method
- Cancer type, stage, and general condition
- Previous treatments and timing of progression
- Imaging and other biomarker results
A practical next step
- 1Save the KRAS G12C result with its source report.
- 2Record previous treatment and when the response changed.
- 3Use the summary to discuss treatment options or potentially relevant trials.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Prepare a KRAS G12C case summary
Keep the biomarker, treatment history, and main question in one context before requesting a review.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Continue exploring
Use a case summary, not a copied medical history
The Cancer Passport keeps the information you choose to save in one place so a later review can start from the same context.
Ready to take the next step?
Start with the information you have. A navigator can help identify what to review next.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.